These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2770113)

  • 1. Intraperitoneal deferoxamine therapy for iron overload in children undergoing CAPD.
    Andreoli SP; Cohen M
    Kidney Int; 1989 Jun; 35(6):1330-5. PubMed ID: 2770113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine for the treatment of hemosiderosis during CAPD.
    Gomez RA; Campbell F; Savory J; Chevalier RL
    Int J Pediatr Nephrol; 1987; 8(1):21-4. PubMed ID: 3583552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda.
    Rocchi E; Gibertini P; Cassanelli M; Pietrangelo A; Borghi A; Ventura E
    J Lab Clin Med; 1986 Jan; 107(1):36-42. PubMed ID: 3941293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron removal during continuous ambulatory peritoneal dialysis using deferoxamine.
    Falk RJ; Mattern WD; Lamanna RW; Gitelman HJ; Parker NC; Cross RE; Rastall JR
    Kidney Int; 1983 Jul; 24(1):110-2. PubMed ID: 6620847
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis.
    Blumberg AB; Marti HR; Graber CG
    JAMA; 1983 Dec 23-30; 250(24):3317-9. PubMed ID: 6645029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum and deferoxamine kinetics in CAPD.
    Mactier RA
    Adv Perit Dial; 1991; 7():26-9. PubMed ID: 1680440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum bactericidal activity for Yersinia enterocolitica in hemodialysis patients: effects of iron overload and deferoxamine.
    Gaughan WJ; Beserab A; Stein HD; Sirota RA; Yudis M
    Am J Kidney Dis; 1992 Feb; 19(2):144-8. PubMed ID: 1739096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate.
    Mossey RT; Wielopolski L; Bellucci AG; Wilkes BM; Chandra M
    Am J Kidney Dis; 1988 Jul; 12(1):40-4. PubMed ID: 3389353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction of haemodialysis-associated anaemia by deferoxamine. Effects on serum aluminum and iron overload.
    von Bonsdorff M; Sipilä R; Pitkänen E
    Scand J Urol Nephrol Suppl; 1990; 131():49-54. PubMed ID: 2075470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F; Mautone A; Cavallo L; Altomare M; Montagna O; Dell'Edera L
    Acta Haematol; 1981; 66(2):96-101. PubMed ID: 6794319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
    Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
    Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of hepatic computed tomography to detect iron overload in chronic hemodialysis.
    Cecchin E; De Marchi S; Querin F; Marin MG; Fiorentino R; Tesio F
    Kidney Int; 1990 Mar; 37(3):943-50. PubMed ID: 2313982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda.
    Rocchi E; Cassanelli M; Borghi A; Paolillo F; Pradelli M; Pellizzardi S; Vezzosi A; Gallo E; Baccarani Contri M; Ventura E
    Dermatologica; 1991; 182(1):27-31. PubMed ID: 2013352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful treatment of haemodialysis-related porphyria cutanea tarda with deferoxamine].
    Pitche P; Corrin E; Wolkenstein P; Revuz J; Bagot M
    Ann Dermatol Venereol; 2003 Jan; 130(1 Pt 1):37-9. PubMed ID: 12605155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
    Seifert A; von Herrath D; Schaefer K
    Q J Med; 1987 Dec; 65(248):1015-24. PubMed ID: 3455553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.